home / stock / cmvlf / cmvlf short
Short Information | Cellectis Romainville Ord (OTCMKTS:CMVLF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 4,816 |
Total Actual Volume | 6,116 |
Short Trends | |
---|---|
Cover Days | 1 |
Short Days | 19 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 241 |
Average Short Percentage | 79.99% |
Is there a CMVLF Short Squeeze or Breakout about to happen?
See the CMVLF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-18-2024 | $0 | $2.6 | $0 | $0 | 40 | 40 | 100% |
03-21-2024 | $2.48 | $2.59 | $2.59 | $2.48 | 400 | 300 | 75% |
03-18-2024 | $0 | $2.59 | $0 | $0 | 1 | 1 | 100% |
03-14-2024 | $2.59 | $2.59 | $2.59 | $2.59 | 100 | 100 | 100% |
03-08-2024 | $2.75 | $2.63 | $2.79 | $2.63 | 400 | 300 | 75% |
03-05-2024 | $2.42 | $2.35 | $2.42 | $2.35 | 300 | 200 | 66.67% |
03-01-2024 | $2.46 | $2.56 | $2.56 | $2.46 | 200 | 100 | 50% |
02-27-2024 | $2.66 | $2.66 | $2.66 | $2.66 | 200 | 200 | 100% |
02-21-2024 | $2.71 | $2.8 | $2.8 | $2.71 | 500 | 500 | 100% |
02-08-2024 | $3.04 | $3.09 | $3.09 | $3.04 | 200 | 200 | 100% |
01-29-2024 | $2.8744 | $2.95 | $2.95 | $2.8744 | 300 | 200 | 66.67% |
01-19-2024 | $2.68 | $2.73 | $2.73 | $2.68 | 1,000 | 900 | 90% |
01-17-2024 | $2.63 | $2.64 | $2.64 | $2.63 | 500 | 100 | 20% |
01-08-2024 | $2.84 | $2.93 | $2.93 | $2.84 | 200 | 200 | 100% |
01-05-2024 | $2.92 | $2.92 | $2.92 | $2.92 | 700 | 700 | 100% |
01-04-2024 | $2.98 | $3 | $3 | $2.98 | 200 | 100 | 50% |
01-03-2024 | $2.93 | $2.93 | $2.93 | $2.93 | 145 | 145 | 100% |
12-29-2023 | $3.03 | $2.99 | $3.03 | $2.99 | 200 | 100 | 50% |
12-28-2023 | $3.35 | $3.41 | $3.41 | $3.35 | 230 | 130 | 56.52% |
12-15-2023 | $3.05 | $3.05 | $3.05 | $3.05 | 300 | 300 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Cellectis Romainville Ord Company Name:
CMVLF Stock Symbol:
OTCMKTS Market:
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, ...
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new ...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exp...